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Objective: To perform a time-trend analysis of adherence and cost of antihypertensive   treatment 
over four years.
Methods: A population-based retrospective cohort study was conducted. We included 
subjects $18 years, and newly treated for hypertension with diuretics, beta-blockers, calcium 
channel blockers, angiotensin-converting enzyme inhibitors, or angiotensin receptor blockers 
between 01 January 2004 and 31 December 2007. One-year adherence to antihypertensive 
therapy was calculated and classified as low, low-intermediate, intermediate, high-intermediate, 
and high. The direct cost of antihypertensive medications was evaluated.
Results: We included data for a total of 105,512 patients. The number of newly treated subjects 
decreased from 27,334 in 2004 to 23,812 in 2007, as well as antihypertensive drug therapy cost 
which decreased from �2,654,166 in 2004 to �2,343,221 in 2007. On the other hand, in the same 
time frame, the percentage of adherent newly treated subjects increased from 22.9% to 28.0%. 
Compared with subjects initiated on angiotensin receptor blockers (odds ratio [OR] = 1), the 
risk of nonadherence was higher in those initiated on angiotensin-converting enzyme inhibitors 
(OR = 1.19), combination therapy (OR = 1.44), beta-blockers (OR = 1.56), calcium channel 
blockers (OR = 1.67), and diuretics (OR = 4.28).
Conclusions: The findings of the present study indicate that suboptimal adherence to antihy-
pertensive medication occurs in a substantial proportion of treated patients, and improvements 
in treatment adherence were obtained but are still unsatisfactory.
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Introduction
Hypertension is a major risk factor for cardiovascular disease (CVD). In the majority 
of Western countries, the cost of hypertension and its complications absorbs a large 
and growing share of health care resources.1 In Italy, the expenditure for antihyper-
tensives reached �991.35 million in 2003. Subtracting expenditure due to use of the 
same drugs for diseases other than hypertension (around 15%), total expenditure for 
antihypertensive therapy (AHT) may be considered to be approximately �840 million.2 
Moreover, at the national level, drugs used for CVD continued to show both the high-
est National Health System (NHS) expenditure (37.5%) and the highest consumption 
(49.0%) in 2007.3
AHT has been clearly shown to reduce both cardiovascular and cerebrovascular 
events4–7 and, consequently, to reduce overall health care costs because of better disease 
control and lower rates of adverse outcomes.8–13 The efficacy of pharmacologic treatment 
in reducing blood pressure has also been well demonstrated in regimem of chronic and 
adequately dosed drug use. ClinicoEconomics and Outcomes Research 2010:2 submit your manuscript | www.dovepress.com
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However, evidence-based guidelines have often failed to 
impact clinical practice. In current practice, observational 
studies have shown that 30%–70% of patients with treated 
hypertension does not persist or adhere to treatment.14–19 
These results and the considerable pressure on health care 
systems to provide high-quality care have led several public 
and private organizations to promote initiatives to monitor 
and improve hypertension control. Meanwhile, progressive 
reduction of available financial resources has ushered in a 
series of measures for controlling costs, such as reductions 
in drug prices, prescriptions charges for private citizens, and 
direct distribution of drugs.
The aim of this work is to emphasize the role of adher-
ence to AHT as a key performance indicator in hypertension 
management. In addition to the existing literature, the present 
study adds a time-trend analysis of adherence during last 
years and a pharmacological treatment cost analysis.
Patients and methods
Data source
In Italy the provider of health care for all citizens is the 
NHS, which is organized into local health units (LHU) 
throughout the country. Each LHU, as an autonomous 
body of the NHS, organizes and plans the health care 
system for a specific area so as to provide services in the 
community close to where people live. The LHUs have an 
information network that routinely measures the volumes 
of expenditure generated by the use of health care services 
and collects them into computerized reimbursement data-
bases. The data we used were retrieved from three differ-
ent databases of the LHU of Florence, an area located in 
the center of Italy, which includes approximately 800,000 
beneficiaries: a Beneficiaries’ Database, containing patient 
demographic data, a Medications Prescription Database, 
providing information for each prescription (such as the 
prescribing physician’s number, anatomical-therapeutic-
chemical code of the drug purchased, number of packs, 
number of units per pack, dosages, unit cost per pack and 
prescription date), and a Hospital Discharge Database, that 
includes all hospitalization data, with discharge diagnosis 
codes classified according to the International Classifica-
tion of Diseases, Ninth Revision (ICD-9). The patient code 
links electronically between all three databases. The LHU 
database affords a valuable opportunity to assess the use of 
AHT in a real practice setting. To guarantee patient privacy, 
each subject was assigned an anonymous alpha-numeric 
code. The local ethics committee of the LHU of Florence 
approved this study.
Cohort definition
This was a retrospective cohort study, which included 
only new AHT users, 18 years of age or over, for whom 
all prescription and clinical outcome data over the study 
period were compiled. Patients were included if they had 
received at least one dispensed prescription of AHT (diuret-
ics [ATC code C03, excluding loop diuretics, mainly used 
for heart failure], beta-blockers [C07], calcium channel 
blockers [C08], angiotensin-converting enzyme inhibi-
tors [C09A/B], angiotensin receptor blockers [C09C/D]) 
between 01 January 2004 and 31 December 2007. The date 
of the first purchased AHT was defined as the enrolment 
date. Patients were defined as new users if they had not 
been prescribed any AHT in the 12 months preceding the 
enrolment date.
In line with previously published studies,20 and in 
order to include only patients treated for hypertension, 
we excluded any patient who had been diagnosed with 
heart failure (code 428.X), ischemic heart disease (code 
410–414.X), cerebrovascular disorders (code 430–438.X) 
or other cardiovascular diseases (code 390–400.X, 406–
459.X, excluding the aforementioned diagnosis codes) in 
the 12 months before enrolment. In addition, we excluded 
patients using nitrates in the 12 months preceding treat-
ment initiation because these agents are also indicated in 
conditions other than hypertension. Only patients with 
continuous eligibility for at least 24 months (12 months 
before and 12 months after the enrolment date) were 
included.
Adherence to AHT medication
Adherence to AHT was estimated by calculating the propor-
tion of days (proportion of days covered [PDC]) on which a 
patient had pills available in the time interval of 12 months 
after the enrolment date (follow-up). The interval was 
separated into treatment episodes of continuous AHT use 
based on the method of Catalan.21 A treatment episode was 
measured as the time period between the starting date of the 
first AHT prescription dispensed until the last day supplied 
on the final dispensed AHT prescription. The latter included 
a permissible gap following a final dispensing within the 
specific episode.
Prescriptions filled near the end of the interval contributed 
days until that date. Prescriptions containing more than one 
drug contributed to both the sum of the days’ supply of all drugs 
from the same AHT class (to accommodate any stockpiling) 
and the lower days’ supply drug value of drugs from different 
AHT classes (identifying them as a combined therapy).ClinicoEconomics and Outcomes Research 2010:2 submit your manuscript | www.dovepress.com
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The PDC corresponded to the total of number of days’ 
supply of medication dispensed within each episode divided 
by the total length of the interval and multiplied by 100. 
Consistent with data in the literature,22,23 patients were 
divided into five different categories according to their PDC 
level, ie, low (PDC # 20%), low-intermediate (21%–40%), 
intermediate (41%–60%), high-intermediate (61%–80%), 
or high (.80%). They were further classified according to 
the AHT drug class prescribed at treatment initiation. Cases 
of multiple class medications, such as calcium channel 
  blockers and angiotensin receptor blockers, were identified 
as combined therapy.
Statistical analysis
A four-year descriptive analysis was conducted to evalu-
ate differences in baseline characteristics, use of AHT, and 
adherence levels across the cohorts of patients identified by 
enrolment year from 2004 to 2007.
We summarized data as mean values with standard devia-
tions for continuous variables and as numbers (percentages) 
of subjects for categoric variables. We used Pearson’s chi-
square test and one-way analysis of variance (ANOVA) to 
determine significant differences in baseline characteristics 
across adherence levels.
A multiple logistic regression model was used to esti-
mate odds ratios (OR) and 95% confidence intervals (CI) 
and to identify possible factors significantly associated 
with the risk of nonadherence during 2004–2007. Patients 
who met the inclusion criteria in more than one of the 
four previous cohorts were only included once. The PDC 
was dichotomized, setting a threshold of PDC # 80% to 
identify nonadherent patients. The other covariates in the 
model were age, gender, presence of some medications (at 
least two prescriptions) evaluated in the 12 months before 
the enrolment date, antidiabetic agents (ATC code A10), 
lipid-lowering drugs (C10), cardiac therapy (C01, nitrates 
excluded), drugs for obstructive airways disease (R03), 
platelet inhibitors (B01AC), and initial therapy drug class, 
with angiotensin receptor blockers as the reference. The year 
of treatment initiation was also controlled for to account for 
possible time trends in medication use. Two-tailed P values 
less than 0.05 were considered statistically significant. All 
statistical analyses were conducted using SPSS-Windows 
version 15.0.
Cost analysis
Only the direct cost of AHT was taken into account. In fact, 
although it would be important for the decision-maker to 
consider other direct costs, eg, hospitalizations, control of 
pharmaceutical expenditure is often considered as the rel-
evant maneuver from the public health care provider point 
of view, and hence the authors focused on that aspect.24 
No information on indirect costs was available. Unit costs 
were taken from the Medications Prescriptions Database 
containing Italian NHS purchase prices. Each prescription 
cost was calculated by multiplying the cost per pack by the 
total number of packs. Since each prescription is unequivo-
cally linked to the patient through the personal health code, 
the exact direct cost per patient was also known. Costs were 
adjusted to 2007 prices in the Euro (�) currency.
Results
A total of 31,483 new AHT patients were enrolled in 2004, 
32,888 in 2005, 29,875 in 2006, and 27,456 in 2007, of 
whom 26.2%, 26.8%, 25.4%, and 25.7%, respectively, were 
excluded because of failure to meet our inclusion criteria. In 
2004, 1786 patients were excluded as a result of having been 
hospitalized for a cardiovascular cause before the enrolment 
date (5.7% of enrolled subjects) and a further 2363 patients 
for having used nitrates or loop diuretics in the year prior to 
enrolment (7.5% of enrolled subjects). Corresponding respec-
tive figures for 2005 were 1848 (5.6% of enrolled subjects) 
and 2659 (8.1%); for 2006, 1568 (5.2%) and 2322 (7.8%); 
and for 2007, 1410 (5.1%) and 2234 (8.1%). Therefore, 
27,334 (21.4%), 28,381 (20.9%), 25,985 (19.5%), and 23,812 
(17.8%) subjects were included in the study in 2004, 2005, 
2006, and 2007, respectively. Mean age, gender distribution, 
and use of hypoglycemic drugs, lipid-lowering drugs, cardiac 
agents, drugs for obstructive airways disease, and platelet 
inhibitors are shown in Table 1.
Adherence to AHT
From 2004 to 2007, low adherence decreased from 33.0% to 
28.5%, while high adherence increased from 22.9% to 28.0% 
(Table 2). Intermediate-low and intermediate-high adherence 
slightly decreased and increased, respectively. Intermediate 
adherence remained stable across the study period (from 
10.5% in 2004 to 10.7% in 2007). Low and intermediate-low 
adherence patients were younger (56.9 ± 17.1 and 58.4 ± 16.8 
years, respectively) compared with other levels of adherence 
(Table 3). Prevalence of male gender was proportional to 
levels of adherence. Prevalence of use of hypoglycemic drugs, 
lipid-lowering drugs, and platelet inhibitors increased from 
low- to high-adherence patients. Use of cardiac therapy was 
limited. Prevalence of use of drugs for obstructive airways 
disease decreased with increasing adherence.ClinicoEconomics and Outcomes Research 2010:2 submit your manuscript | www.dovepress.com
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Table 4 shows the initiation AHT. In approximately one-
third of subjects, angiotensin-converting enzyme inhibitors 
were the preferred first-line therapy. In contrast, combination 
therapy was rarely used as first-line therapy. From 2004 to 
2007, the proportion of prescriptions for diuretics decreased 
(from 24.0% to 20.8%), increased slightly for beta-blockers 
(from 14.8% to 16.1%), decreased slightly for calcium chan-
nel blockers (from 9.5% to 7.7%), whilst use of angiotensin-
converting enzyme inhibitors and combinations as starting 
therapy remained stable (35.5% to 35.3% and 4.9% to 5.5%, 
respectively), and use of angiotensin receptor blockers sig-
nificantly increased (from 11.4% to 14.7%).
Adherence levels varied significantly among drugs used 
for treatment initiation (Table 5). In particular, low adher-
ence was highest among subjects started on diuretics (54.7% 
of included subjects) and lowest among those started on 
angiotensin receptor blockers (13.0%). Subjects started on 
a combination therapy showed low adherence in 36.8% of 
cases. High adherence was highest among subjects initiated 
on angiotensin receptor blockers (33.4%) and lowest among 
subjects started on diuretics (10.1%). Subjects starting 
with angiotensin-converting enzyme inhibitors displayed 
high adherence in 29.9% of cases. Compared with subjects 
initiated on angiotensin receptor blockers, the risk of non-
adherence was 19% higher in those initiated on angiotensin-
converting enzyme inhibitors, 44% higher in those initiated 
on combination therapy, 56% higher in those initiated on 
beta-blockers, 67% higher in those initiated on calcium chan-
nel blockers, and more than four-fold (4.3 times) higher in 
those initiated on diuretics (Table 6).
Cost analysis of AHT
The overall cost of AHT for the one-year follow-up was 
�2,654,166 in 2004, �2,664,815 in 2005 (+0.4% compared 
with 2004), �2,339,704 in 2006 (-12.2% compared with 
2005), and �2,343,221 in 2007 (+0.2% compared with 2006 
and -11.7% compared with 2004, Table 7). The percentage 
of overall cost of AHT allocated to high adherence patients 
ranged from 60.7% in 2004, to 59.5% in 2005, 60.6% in 
2006, and 64.9% in 2007. Overall costs allocated to low 
and intermediate-low adherence patients decreased during 
the study period. The mean cost of AHT for the one-year 
follow-up decreased in each level of adherence. In high 
adherence, the mean cost decreased from �256.97 in 2004 
to �228.21 in 2007 (Table 8).
Discussion
Many studies have highlighted poor adherence in subjects 
newly treated with AHT,14–19 but few of them have evaluated 
how adherence levels vary over time.20 The present study pro-
vides some additional information about AHT among newly 
treated patients. First, it measures the number of subjects 
initiating pharmacologic treatment and gives information 
Table 1 Baseline characteristics of patients newly treated with antihypertensive therapy
2004 2005 2006 2007 P value
Patients, n (%*) 27,334 (21.4) 28,381 (20.9) 25,985 (19.5) 23,812 (17.8)
Age, mean (SD), years^ 59.9 ± 15.7 60.1 ± 15.8 59.8 ± 15.7 60.8 ± 15.2 ,0.001
Males (%) 42.1 42.5 42.8 42.6 0.425
Hypoglycaemic drugs (%)† 4.9 5.3 5.3 5.1 0.249
Lipid-lowering drugs (%)† 4.6 4.8 4.5 5.1 0.027
Cardiac therapy (%)† 2.0 1.9 1.8 1.6 0.017
Drugs for obstructive airways disease (%)† 4.6 5.1 4.5 4.4 ,0.001
Platelet inhibitors (%)† 6.7 7.6 6.9 7.7 ,0.001
Notes: *On treated patients; ^At enrolment date; †One year before enrolment date.
Table 2 Time trends for adherence level by enrolment year
Year of treatment  
initiation
Proportion of patients according to adherence level, n (%)*
Low Intermediate-low Intermediate Intermediate-high High Total
2004 9009 (33.0) 6068 (22.2) 2878 (10.5) 3106 (11.4) 6273 (22.9) 27,334 (100.0)
2005 9358 (33.0) 6624 (23.3) 3171 (11.2) 3053 (10.8) 6175 (21.8) 28,381 (100.0) 
2006 8581 (33.0) 5959 (22.9) 2682 (10.3) 2861 (11.0) 5902 (22.7) 25,985 (100.0)
2007 6790 (28.5) 4851 (20.4) 2554 (10.7) 2956 (12.4) 6661 (28.0) 23,812 (100.0)
Notes:  *Adherence  was  defined  as:  low  (PDC  #  20%);  intermediate-low  (PDC,  21%–40%);  intermediate  (PDC,  41%–60%);  intermediate-high  (PDC,  61%–80%);  high 
(PDC . 80%); overall χ² test, P , 0.001.
Abbreviation: PDC, proportion of days covered.ClinicoEconomics and Outcomes Research 2010:2 submit your manuscript | www.dovepress.com
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Table 3 Baseline characteristics of patients by level of adherence to treatment, 2004–2007
Adherence levels*
Low Intermediate-low Intermediate Intermediate-high High P value
Patients, n (%) 30,915 (32.6) 20,933 (22.0) 9,785 (10.3) 10,614 (11.2) 22,700 (23.9)
Age, mean (SD), years^ 56.9 ± 17.1 58.4 ± 16.8 61.9 ± 15.0 62.8 ± 13.6 62.6 ± 12.7 ,0.001
Male (%) 38.2 41.9 41.4 44.7 50.2 ,0.001
Hypoglycaemic drugs (%)† 3.5 4.5 5.2 6.0 7.2 ,0.001
Lipid lowering drugs (%)† 3.7 4.2 5.2 5.5 5.8 ,0.001
Cardiac therapy (%)† 1.5 1.8 1.8 1.9 2.0 ,0.001
Drugs for obstructive airways 
disease (%)†
5.2 5.0 4.1 3.8 3.9 ,0.001
Platelet inhibitors (%)† 5.5 6.4 8.0 8.2 8.6 ,0.001
Notes: *Adherence was defined as: low (PDC # 20%); intermediate-low (PDC, 21%–40%); intermediate (PDC, 41%–60%); intermediate-high (PDC, 61%–80%); high 
(PDC . 80%). ^At the enrolment date; †One year before enrolment date.
Abbreviation: PDC, proportion of days covered.
Table 4 Antihypertensive drug classes used at treatment initiation
2004 2005 2006 2007 Total
Diuretics, n (%) 6553 (24.0) 6254 (22.0) 5686 (21.9) 4955 (20.8) 23,448 (22.2)
Beta-blockers, n (%) 4059 (14.8) 4129 (14.5) 3877 (14.9) 3826 (16.1) 15,891 (15.1)
Calcium channel blockers, n (%) 2594 (9.5) 2641 (9.3) 2316 (8.9) 1822 (7.7) 9373 (8.9)
Angiotensin-converting enzyme  
inhibitors, n (%)
9691 (35.5) 9706 (34.2) 8857 (34.1) 8414 (35.3) 36,668 (34.8)
Angiotensin receptor  
blockers, n (%)
3103 (11.4) 3871 (13.6) 3585 (13.8) 3496 (14.7) 14,055 (13.3)
Combined therapy, n (%) 1334 (4.9) 1780 (6.3) 1664 (6.4) 1299 (5.5) 6077 (5.8)
Note: Overall χ² test, P , 0.001.
on patient characteristics and cost of AHT over time. From 
2004 to 2007, there was a 12.9% decrease in the number of 
patients initiated on AHT (from 21.4% to 17.8%) as well as 
an 11.7% decrease in the overall cost of AHT for the one-
year follow-up (from �2,654,166 in 2004 to �2,343,221 in 
2007). This findings may be the result of reductions both in 
the number of patients started on AHT and in drug prices, 
rather than attributable to a shift in prescribing preferences for 
cheaper therapeutic options (see Table 4). These preliminary 
findings seem to show a trend towards economic savings 
in pharmaceutical expenditure by reducing the number of 
patients starting AHT. In particular, the reduction of initi-
ated patients refers to low adherence (from 9009 to 6790 
patients) and to low-intermediate adherence (from 6068 to 
4851 patients) but does not refer to higher levels of adher-
ence (Table 2). Because low and low-intermediate adherence 
patients indicate a lower risk compared with those with higher 
adherence (Table 3), these findings seem to underline a thera-
peutic approach strategy which pays more attention to patient 
characteristics before initiating pharmacologic treatment. 
Understanding how patient adherence to pharmacologic 
treatment varies on the basis of demographic and clinical 
characteristics, decision-makers could better focus on those 
categories of patients who are more likely not to adhere to 
treatment, ie, younger men and those taking no concomitant 
cardiovascular medications (Tables 3 and 4). This strategy 
could be particularly effective, especially if the resources 
saved could be reallocated to priority patients, ie, those at 
higher risk of CVD and those who need improvement in 
their adherence.
Second, a high amount of AHT expenditure was accounted 
for by nonadherent patients, although this decreased over time 
(from 39.3% of the overall cost in 2004 to 35.1% in 2007). 
Resources allocated to regimes not adhered to can be con-
sidered inappropriate both in the short term (because blood 
pressure is not effectively controlled) and in the long term 
(because the opportunity to decrease the costs of cardiovas-
cular complications is missed).
Third, the present four-year analysis of adherence shows 
a low rate of increase in adherence (from 22.9% in 2004 to 
28.0% of newly treated subjects in 2007) suggesting the need 
for more effective interventions. Recently, the EUROASPIRE 
III (European Action on Secondary and Primary Prevention 
by Intervention to Reduce Events III) survey showed that 
blood pressure control did not improve with time, and indeed 
showed a 10% worsening over the three survey periods.25 ClinicoEconomics and Outcomes Research 2010:2 submit your manuscript | www.dovepress.com
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The low increase in rates of adherence would indicate no 
increase in the proportion of patients achieving blood pres-
sure control in clinical practice. As shown in recent studies, 
failures in reaching high adherence with AHT implies avoid-
able CVD hospitalizations and deaths8–13 and increasing costs 
for the management of hypertension and related diseases.1,11,26 
In 2003, the World Health Organization alerted health 
authorities and clinicians about poor adherence to chronic 
pharmacologic treatments in clinical practice and suggested 
the need for action.27 According to existing evidence, more 
effective interventions should be planned and developed. 
Discordance also between the ideal scenario and the results 
obtained from our study should increase awareness among 
health care providers of the need for better performance. 
From the perspective of enhancing treatment adherence, use 
of angiotensin receptor blockers as first-line therapy should 
be considered because these agents have shown the highest 
rates of high adherence and, above all, the lowest rate of early 
discontinuation (Table 5). Our findings with regard to poor 
adherence should be considered both by clinicians when 
selecting first-line therapy and by health care providers when 
defining their pharmaceutical formularies.
Limitations
The principal limitation of this study is its lack of inclusion 
of patient clinical data. The study was conducted by cross-
linking administrative databases. These ad hoc databases are 
comparable with the health care claims databases which have 
been utilized for outcomes research for years in the US and 
Canada. 28,29 Because these databases are normally used for 
administrative or accounting purposes, they omit information 
that would make it possible to determine the clinical status of 
patients. The absence of clinical outcomes data, in particular 
blood pressure control, could have generated bias, leading to 
comparisons of patients with different levels of disease sever-
ity. In addition, the data source does not provide any informa-
tion about the diagnosis of hypertension, thus the possibility 
of disease misclassification cannot be excluded. Moreover, 
information about patient lifestyle habits and health status 
information, ie, physical activity levels, smoking status, and 
other determinants of CVD morbidity and mortality, were 
not available. The potential confounding effect of this lack of 
information on the association between adherence to antihy-
pertensives and CVD events should be investigated.
Table 5 Antihypertensive drug classes used at treatment initiation according to adherence level, 2004–2007
Adherence levels*
Low Intermediate-low Intermediate Intermediate-high High
Diuretics, n (%) 11,533 (54.7) 4214 (20.0) 1709 (8.1) 1479 (7.0) 2133 (10.1)
Beta-blockers, n (%) 3081 (21.9) 3969 (28.2) 2017 (14.3) 1886 (13.4) 3120 (22.2)
Calcium channel  
blockers, n (%)
2494 (29.2) 2315 (27.1) 980 (11.5) 820 (9.6) 1932 (22.6)
Angiotensin-converting  
enzyme inhibitors, n (%)
10,137 (30.5) 5508 (16.6) 3246 (9.8) 4370 (13.2) 9922 (29.9)
Angiotensin receptor  
blockers, n (%)
1637 (13.0) 3825 (30.4) 1357 (10.8) 1544 (12.3) 4202 (33.4)
Combined therapy, n (%) 2033 (36.8) 1102 (20.0) 476 (8.6) 515 (9.3) 1391 (25.2)
Notes: *Adherence was defined as: low (PDC # 20%); intermediate-low (PDC, 21%–40%); intermediate (PDC, 41%–60%); intermediate-high (PDC, 61%–80%); high 
(PDC . 80%). Overall χ² test, P , 0.001.
Abbreviation: PDC, proportion of days covered. 
Table  6  Multivariate  analysis  of  the  association  of  initial 
antihypertensive drug class with nonadherence to treatment
OR (95% CI) P value
Age, years^ 0.98 (0.98–0.98) ,0.001
Gender 
  Male 1.00
  Female 0.74 (0.72–0.77) ,0.001
Year of start
  2004–2005 1.00
  2006–2007 0.86 (0.80–0.92) ,0.001
Medications before the enrolment 
date*†
  Hypoglycaemic drugs 0.78 (0.73–0.83) ,0.001
  Lipid-lowering drugs 0.86 (0.80–0.92) ,0.001
  Cardiac therapy 0.98 (0.87–1.10) 0.663
  Drugs for obstructive airways disease 1.24 (1.15–1.35) ,0.001
  Platelet inhibitors 0.98 (0.93–1.04) 0.579
Enrolment drug class
  Angiotensin receptor blockers 1.00
    Angiotensin-converting enzyme  
inhibitors
1.19 (1.14–1.24) ,0.001
  Combined therapy 1.44 (1.34–1.55) ,0.001
  Beta-blockers 1.56 (1.47–1.65) ,0.001
  Calcium channel blockers 1.67 (1.57–1.78) ,0.001
  Diuretics 4.28 (4.04–4.54) ,0.001
A total of 94,947 patients were considered in the model.
Notes: ^At enrolment date; *Absence of medication as reference; †One year before 
enrolment date.ClinicoEconomics and Outcomes Research 2010:2 submit your manuscript | www.dovepress.com
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Another important limitation related to the source of the 
data is the lack of information on the indication for AHT. 
To increase the likelihood that AHT was used for hyperten-
sion, patients with known CVD were excluded from the 
study. Moreover, the available data included only drugs 
dispensed, rather than drugs consumed. Therefore, we may 
have overestimated adherence. However, the data suggest a 
good correlation between pharmacy dispensing records and 
cumulative drug exposure.22 Finally, only direct costs were 
included, but indirect and intangible costs have no actual 
financial implications for health care structure and should 
be considered only for a societal perspective.1
Conclusions
The findings of the present study show that adherence to 
AHT improved slowly from 22.9% to 28.0% in newly treated 
subjects over four years. Local services should therefore be 
alerted to the need for routine monitoring of adherence to 
AHT, because this is a key performance indicator for both 
management of hypertensive patients and overall cost mini-
mization in CVD. Administrative databases, even if lacking 
patient lifestyle and health status information, offer a low-
cost monitoring option, and include sufficiently accurate data 
for representative populations.
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